Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Liposomal amikacin · Amikin, Amikin In Sodium Chloride 0.9% In Plastic Container

Small molecule · developed by Insmed

Approved FDA, Sep 2018
INSM Developer
1 Registered trials

What is Liposomal amikacin?

Liposomal amikacin is an inhaled aminoglycoside antibacterial delivered as a liposomal dispersion via nebulization.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Amikin, Amikin In Sodium Chloride 0.9% In Plastic Container, Arikayce
Drug type
Small molecule
Therapy area
Infectious disease, Respiratory
Developer
Insmed Inc (INSM)
FDA status
Approved as Amikin, Amikin In Sodium Chloride 0.9% In Plastic Container, Arikayce (September 28, 2018), NDA207356 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 4, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01315678 Phase 3 Pseudomonas Aeruginosa Infection Completed INSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pseudomonas Aeruginosa Infection

More from Insmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.

Follow INSM, the company behind Liposomal amikacin

See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INSM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.